Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets


Out-
      side
 



 
 'GE Healthcare' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'GE Healthcare' found in 1 term [] and 22 definitions []
1 - 5 (of 23)     next
Result Pages : [1]  [2 3 4 5]
Searchterm 'GE Healthcare' was also found in the following services: 
spacer
News  (67)  Resources  (28)  
 
GE HealthcareMRI Resource Directory:
 - Manufacturers -
 
www.gehealthcare.com GE Healthcare is the result of the merger between GE Medical and Amersham Health in Nov. 2004, after GE acquired Amersham Health for 9.5 billion in Oct. 2003. Jeffrey R. Immelt, Chairman of the Board and Chief Executive of General Electric, said, 'Amersham's diagnostic pharmaceutical and life sciences business will add new, high growth platforms to GE Medical's diagnostic imaging, services and healthcare information technology businesses'. GE Healthcare, a UK company, is a unit of General Electric (NYSE: GE). GE Healthcare is a global leader in medical imaging, diagnostic imaging contrast agents, interventional procedures, healthcare services, and information technology. For more than 100 years, health care providers have relied on GE Medical Systems, now GE Healthcare, for high quality medical technology and productivity solutions. GE Healthcare, headquartered now at formerly seat of Amersham Health in Great Britain, operates facilities around the world. Global Operations include organizations on the Americas, Europe, and Asia, including India, Japan, Korea China, Thailand and Vietnam.

MRI Related Product Lines:

Devices:
Signa HDx 3.0T
Signa HDx 1.5T
Signa HDe 1.5T
Signa 3.0T™
Signa Infinity 1.5T™ with Excite

Signa Infinity 1.5T™ TwinSpeed with Excite

Signa OpenSpeed™
Signa Ovation™
Signa Profile™

Older

SIGNA SP 0.5T™ Open Configuration
Signa Infinity 1.0T™

Contrast Agents:
Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
Omniscan®
Teslascan®
Clariscan™


Contact Information
ONLINE www.gehealthcare.com
CONTACT INFO PAGE www.gehealthcare.com/contact
spacer
 
• Share the entry 'GE Healthcare':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'GE Healthcare' (26).Open this link in a new window.
 
Further Reading:
  Basics:
GE Medical's new name: GE Healthcare
Friday, 6 February 2004   by milwaukee.bizjournals.com    
  News & More:
MR Surgical Suite, Improving surgical procedure quality (.pdf)
   by www3.gehealthcare.com    
RSNA update on new MRI technology(.pdf)
February 2006   by www.magnet-mri.org    
MRI's inside story
Thursday, 4 December 2003   by www.economist.com    
Searchterm 'GE Healthcare' was also found in the following services: 
spacer
Radiology  (8) Open this link in a new windowUltrasound  (14) Open this link in a new window
Omniscan®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Omniscan® is a nonionic chelate complex with low osmolality used as a paramagnetic MRI contrast agent. The efficacy of Omniscan® is similar to that of Gd-DTPA. Omniscan® is given intravenously to enhance images of intracranial and spinal lesions where there is abnormal vascularity or an abnormal blood brain barrier. The complex does not cross an intact blood brain barrier so Omniscan® only accumulates in lesions such as neoplasm's and abscesses.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Gadodiamide, and Classifications, Characteristics, etc.

Drug Information and Specification
NAME OF COMPOUND Gadodiamide, Gd-DTPA-BMA
DEVELOPER Winthrop Laboratories
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.9, r2=4.3, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 798 mosm/kgH2O
CONCENTRATION 287 mg/mL,0.5 mol/L
DOSAGE 0.1-0.2 mmol/kg / 0.2-0.4 ml/kg
PREPARATION Finished product
INDICATION Neuro/whole body
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 10 mL, 15 mL and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA Omniscan® for sale GE Healthcare
EU Omniscan® for sale GE Healthcare
Australia Omniscan® for sale GE Healthcare

spacer

• View the DATABASE results for 'Omniscan®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
Omniscan Pharmacokinetics
  News & More:
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
October 2004   by www.findarticles.com    
MRI Resources 
Nerve Stimulator - - Implant and Prosthesis - NMR - Equipment - Education
 
GE LunarMRI Resource Directory:
 - Manufacturers -
 
www.gehealthcare.com [This entry is marked for removal.]

General Electric (GE) agreed to buy diagnostic systems maker Lunar Corp. for $150m. in March 2000. In 2004/05 it seems that the integration process into GE Healthcare has been completed. (GE Medical Systems and Amersham announced in April 2004 the completion of a share exchange acquisition of Amersham Health by GE. The result of this acquisition is the new GE Healthcare, based in the UK, totally owned by General Electric (GE).

The U.S.-based company developed bone densitometers and scanning machines that measure bone density as a way of diagnosing osteoporosis and other metabolic bone diseases. GE Lunar marketed these products worldwide.
GE Lunar announced a distribution agreement with MagneVu for domestic sales of the MagneVu 1000, a portable MRI device for orthopedic use, under the trade name Applause™.
GE Lunar was the exclusive U.S. distributor of MR-devices manufactured by Esaote S.p.A. These compact in-office MRI™ machines are designed to fit all practice sizes in orthopedic imaging and complete the range of diagnostic imaging systems.
spacer

• View the DATABASE results for 'GE Lunar' (2).Open this link in a new window

 
Further Reading:
  News & More:
Portable MR system aids diagnosis of rheumatic diseases
Sunday, 12 January 2003   by www.diagnosticimaging.com    
Searchterm 'GE Healthcare' was also found in the following services: 
spacer
News  (67)  Resources  (28)  
 
Signa HDe 1.5T™InfoSheet: - Devices -
Intro, 
Types of Magnets, 
Overview, 
etc.
 
From GE Healthcare;
www.vitalcom.com/euen/mri/products/signa-hde-15t/index.html GE Healthcare has added the Signa HDe 1.5T™, a compact MRI device at an affordable price to its family of MRI products. It has a single electronic cabinet that can be positioned inside the scanner room rather than in a separate equipment room. The Signa HDe 1.5T can be installed in the same physical location as 0.5T MRI systems with minimal construction costs. According to GE, the installation has been simplified to last only 7 days and has a 30 percent smaller footprint than a typical 1.5T system.
The 1.5T Signa® HDe MRI system is substantially equivalent to the currently marketed GE 1.5T machines. The data acquisition system supports 1, 4, 8 independent receive channels and multiple independent coil elements per channel during a single acquisition series. The gradient specifications of HDe are lower than other GE Signa 1.5T MRI systems, but it can support clinical applications in cardiac and spectroscopy imaging.

Device Information and Specification
CLINICAL APPLICATION Whole body
CONFIGURATION Compact short bore
SURFACE COILS Head and body coil standard; all other coils optional e.g., abdomen, spine, breast, knee, shoulder, cardiac imaging coils
SPECTROSCOPY Possible
SYNCHRONIZATION ECG/peripheral, respiratory gating, (SmartPrep, SmartStep)
PULSE SEQUENCES Standard: SE, IR, 2D/3D GRE and SPGR, Angiography: 2D/3D TOF, 2D/3D Phase Contrast; 2D/3D FSE, 2D/3D FGRE and FSPGR, SSFP, FLAIR, EPI
IMAGING MODES 2D single slice, multi slice, and 3D volume images, multi slab, cine
FOV 1 cm to 48 cm continuous
SLICE THICKNESS 2D 0.7 mm to 20 mm; 3D 0.1 mm to 5 mm
DISPLAY MATRIX 1028 x 1024
MEASURING MATRIX 128x512 steps 32 phase encode
PIXEL INTENSITY 256 gray levels
MAGNET TYPE Superconducting
POWER REQUIREMENTS 480 or 380/415
COOLING SYSTEM TYPE Closed-loop water-cooled gradient
CRYOGEN USE, L/hr less than 0.03 L/hr liquid helium
FIELD STRENGTH 1.5 T
spacer

• View the NEWS results for 'Signa HDe 1.5T™' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Signa HDe 1.5T
   by www.gehealthcare.com/    
Searchterm 'GE Healthcare' was also found in the following services: 
spacer
Radiology  (8) Open this link in a new windowUltrasound  (14) Open this link in a new window
Teslascan®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
(Mn-DPDP) This agent, mangafodipir trisodium, is a hepatocyte specific MRI contrast agent. Manganese is very toxic, so it has to be chelated and put in the form of a vitamin B6 analog, which is taken up by normal hepatocytes to some extent.
Teslascan® was developed in the early 1980's, went through clinical trials in the early 1990's, and was approved in 1997. One problem with assessing the efficacy of this agent is the fact that the phase III trials finished in the early 1990's, and the techniques used for MR today are very different from the techniques used almost a decade ago.
This contrast agent shortens the T1 relaxation time. On T1 weighted pictures it makes a normal liver look brighter. Since metastases, for example, do not generally take up this agent, the contrast between the enhancing liver and the non-enhancing lesions will increase on T1 weighted pictures. It does not have much effect on T2 weighted images.

Drug Information and Specification
NAME OF COMPOUND Mangafodipir trisodium, Manganese dipyroxyl diphosphate, MN-DPDP
DEVELOPER Amersham plc
CENTRAL MOIETY Mn2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=2.3, r2=4.0, B0=1.0 T
PHARMACOKINETIC Hepatobiliary, pancreatic, adrenal
OSMOLALITY 290 mosm/kgH2O
CONCENTRATION 0.01 mmol/L
DOSAGE 5 µmol/kg, 0.5 ml/kg
PREPARATION Finished product
INDICATION Liver lesions
DEVELOPMENT STAGE Approved
DISTRIBUTOR See below
PRESENTATION Vials of 100 ml
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA Teslascan® for sale GE Healthcare
EU Teslascan® for sale GE Healthcare

spacer

• View the DATABASE results for 'Teslascan®' (4).Open this link in a new window

 
Further Reading:
  Basics:
EMEA - Teslascan - SCIENTIFIC DISCUSSION(.pdf)
   by www.emea.europa.eu    
  News & More:
Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.
2002
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
MRI Resources 
DICOM - Spectroscopy - RIS - Equipment - Spectroscopy pool - Intraoperative MRI
 
     1 - 5 (of 23)     next
Result Pages : [1]  [2 3 4 5]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



Your new MRI scanner in 2020 will be shipped from :
China 
Europe 
India 
Japan 
USA 
other 

Look
      Ups





Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2014 SoftWays. All rights reserved. [ 31 October 2014]
Terms of Use | Privacy Policy | Advertising
 [last update: 2014-10-27 05:24:54]